

APPROVED

By Jean Gildner at 10:12 am, Jul 19, 2016

From: [Margarita Aguilera](#)
To: [Gildner, Jean](#)
Cc: [Yao, Michael \(CBER\)](#)
Subject: FW: Request for additional clinical information
Date: Tuesday, June 07, 2016 11:02:30 AM
Attachments: [Response to FDA Request for Information May 23 2016 \(1\).docx](#)
[Response to Request for Information Patient Consented.pdf](#)
[maci0206 Listing 16 1 2 1.pdf](#)
[Response Information Request April 2016.pdf](#)
[Listing 16 -1-1-3.pdf](#)

Hi Jean,

In response to your email today, I am forwarding the email sent to Dr. Yao on May 26, 2016. My apologies for not including you in our response.

Regards,
Margarita

Margarita Aguilera, M.Sc.
Senior Regulatory Consultant – Vericel Corporation
64 Sidney Street
Cambridge, MA 02139
maguilera@vcel.com
Telephone: (617) 588-5661
Mobile: (224) 659-2129
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

From: Margarita Aguilera
Sent: Thursday, May 26, 2016 4:51 PM
To: 'Yao, Michael (CBER)'
Cc: Schneider, Bruce
Subject: RE: Request for additional clinical information

Dear Dr. Yao,

Attached please find responses to the questions raised in your email dated May 23, 2016.

Please let me know if additional information or clarification is needed.

Regards,
Margarita

Margarita Aguilera, M.Sc.
Senior Regulatory Consultant – Vericel Corporation
64 Sidney Street
Cambridge, MA 02139
maguilera@vcel.com;
Telephone: (617) 588-5661
Mobile: (224) 659-2129
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

From: Yao, Michael (CBER) [<mailto:Michael.Yao@fda.hhs.gov>]
Sent: Thursday, May 26, 2016 2:03 PM
To: Margarita Aguilera
Cc: Schneider, Bruce
Subject: RE: Request for additional clinical information

Thanks.

Michael

From: Margarita Aguilera [<mailto:maguilera@vcel.com>]
Sent: Thursday, May 26, 2016 2:02 PM
To: Yao, Michael (CBER)
Cc: Schneider, Bruce
Subject: RE: Request for additional clinical information

Dear Dr. Yao,

Thanks for resending. I will discuss with the team and get back to you as soon as possible.

Regards,
Margarita

Margarita Aguilera, M.Sc.
Senior Regulatory Consultant – Vericel Corporation
64 Sidney Street
Cambridge, MA 02139

maguilera@vcel.com;

Telephone: (617) 588-5661

Mobile: (224) 659-2129

Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

From: Yao, Michael (CBER) [<mailto:Michael.Yao@fda.hhs.gov>]

Sent: Thursday, May 26, 2016 2:00 PM

To: Margarita Aguilera

Cc: Schneider, Bruce

Subject: FW: Request for additional clinical information

Importance: High

Hi Margarita,

Have you received below request for the clinical information?

Thanks

Michael

From: Yao, Michael (CBER)

Sent: Monday, May 23, 2016 11:02 AM

To: 'Margarita Aguilera'

Cc: Schneider, Bruce; Gildner, Jean

Subject: RE: Request for additional clinical information

Margarita,

Thanks for your response. BTW, we still have following questions to you:

1. Regarding subject screen and re-screen, please provide tabulation of reasons for screen failure in 45 or so subjects out of the original 189 subjects. Also, please provide details of rescreen (tabulation).
2. Please indicate where we can find information on the randomization procedure, in particular, how the surgeon was informed of the randomization assignment during the arthroscopy procedure.
3. Also, for those subjects with prior surgery to the index knee (prior to screening), please

provide information regarding the type of surgery for each subject, along with subject number.

Thanks,

Michael

From: Margarita Aguilera [<mailto:maguilera@vcel.com>]
Sent: Sunday, May 22, 2016 10:04 PM
To: Yao, Michael (CBER)
Cc: Schneider, Bruce; Gildner, Jean
Subject: RE: Request for additional clinical information

Dear Dr. Yao,

This is to acknowledge receipt of your request for information. I will get back to you with additional information on Monday.

Regards,
Margarita

Margarita Aguilera, M.Sc.
Senior Regulatory Consultant – Vericel Corporation
64 Sidney Street
Cambridge, MA 02139
maguilera@vcel.com;
Telephone: (617) 588-5661
Mobile: (224) 659-2129
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

From: Yao, Michael (CBER) [<mailto:Michael.Yao@fda.hhs.gov>]
Sent: Friday, May 20, 2016 9:02 PM
To: Margarita Aguilera
Cc: Schneider, Bruce; Gildner, Jean
Subject: Request for additional clinical information
Importance: High

Hi Aguilera,

Please provide following information for us:

1. Regarding clinical evaluation in SUMMIT study, do you have clinical data (KOOS pain and function) before visit 6 (week 24)? If so, please provide a summary for FDA review.
2. Please provide subgroup analysis by number of lesions and by subject age, using some reasonable cut-off determine "younger" vs "older."

Thanks.

Michael